[Skip to Navigation]
The Cutting Edge: Challenges in Medical and Surgical Therapies
June 2012

Angiosarcoma of the Scalp Successfully Treated With a Single Therapy of Sorafenib

Author Affiliations
 

SECTION EDITOR: EDWARD W. COWEN, MD, MHSc; ASSISTANT SECTION EDITORS: MURAD ALAM, MD; RUTH ANN VLEUGELS, MD

Arch Dermatol. 2012;148(6):683-685. doi:10.1001/archdermatol.2011.2819

Angiosarcoma (AS) of the scalp is a rare and aggressive neoplasm with one of the worst prognoses among malignant skin tumors. The overall 5-year survival rate is less than 30%.1 Specific treatment guidelines are absent, and treatment options include surgical excision, radiation therapy, chemotherapy (CT), and biological therapy such as recombinant interleukin 2 (rIL-2). Surgical excision with negative margins combined with CT is the most successful strategy for improving the prospect for survival.2,3

Add or change institution
×